Imageens’ AI-enabled medical image analysis platform augments doctors' ability to deliver precision and personalized medicine in cardiovascular health.
By applying AI and biomechanical modelling to cardiovascular MRI data, we seamlessly provide valuable medical insights that inform important treatment decisions in cardiovascular diseases (CVDs).
Imageens' first target CVD is severe asymptomatic carotid stenosis, a disease affecting 5-10% of the population over 65 and causing 15-20% of ischemic strokes. Today, operatory decisions for carotid stenoses are based on vascular surgeons' personal judgement, which leads to errors in who gets operated, excess costs, and avoidable deaths.
Our platform will allow vascular surgeons to accurately predict the risk of stroke for each patient, and thus make a precise and personalized decision to operate the patient or not. The benefit for our clients – vascular surgery hospital units in the US and west EU – will be the ability to improve medical care delivered to patients, ensure high risk patients are prioritized, and increase the cost effectiveness of their operations.
We estimate the market size for our carotid stenosis product to be in the range of EUR 400-600Mn in revenues per year by 2023.
Imageens’ is in a prime position to deliver on this mission thanks to the extensive clinical validation of its algorithms in large US clinical trials (NIH funded MESA trial; 6000 patients) and the profile of its team.